移植前后微小残留病可预测儿童急性淋巴细胞白血病复发
该回顾性研究纳入119例完全缓解期接受异基因造血干细胞移植的儿童急性淋巴细胞白血病患者,用聚合酶链反应检测移植前及移植后第一、第三 trimester 的微小残留病。移植前任何可检测的微小残留病均与不良结局相关,移植后微小残留病持续与极差结局相关。
要点
- 移植前可检测到微小残留病者无事件生存率低于微小残留病阴性者。
- 移植后微小残留病持续与极差结局相关。
- 移植后微小残留病持续者或可从早期停用免疫抑制或抢先免疫治疗中获益。
核心结论
- 微小残留病是移植前后重要的预后因素。
- 鉴于移植后微小残留病持续与极差结局相关,这些患者或可从早期停用免疫抑制或抢先免疫治疗中获益。
研究设计与样本
- 回顾性研究,纳入119例完全缓解期接受异基因造血干细胞移植的儿童急性淋巴细胞白血病患者。
- 用聚合酶链反应检测移植前及移植后第一、第三 trimester 骨髓样本中的微小残留病。
主要发现
- 总体无事件生存率为50%。
- 复发累积发生率为41%,非复发死亡累积发生率为9%。
- 移植前微小残留病阳性<1×10⁻³者无事件生存率为39%,≥1×10⁻³者为18%,微小残留病阴性者为73%(P<0.001)。
- 移植后第一至第三 trimester 微小残留病增加可清晰区分结局不同的队列。
临床怎么用
- 作者认为,移植后微小残留病持续的患者或可从早期停用免疫抑制或抢先免疫治疗中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse remains the leading cause of treatment failure in children with acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem cell transplantation (HSCT). We retrospectively investigated the prognostic role of minimal residual disease (MRD) before and after HSCT in 119 children transplanted in complete remission (CR). MRD was measured by polymerase chain reaction in bone marrow samples collected pre-HSCT and during the first and third trimesters after HSCT (post-HSCT1 and post-HSCT3). The overall event-free survival (EFS) was 50%. The cumulative incidence of relapse and non-relapse mortality was 41% and 9%. Any degree of detectable pre-HSCT MRD was associated with poor outcome: EFS was 39% and 18% in patients with MRD positivity <1 × 10-3 and ≥1 × 10-3 , respectively, versus 73% in MRD-negative patients (P < 0·001). This effect was maintained in different disease remissions, but low-level MRD had a very strong negative impact only in patients transplanted in second or further CR. Also, MRD after HSCT enabled patients to be stratified, with increasing MRD between post-HSCT1 and post-HSCT3 clearly defining cohorts with a different outcome. MRD is an important prognostic factor both before and after transplantation. Given that MRD persistence after HSCT is associated with dismal outcome, these patients could benefit from early discontinuation of immunosuppression, or pre-emptive immuno-therapy.
引用
- Lovisa F, Zecca M, Rossi B, et al. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018. PMID: 29359790. doi:10.1111/bjh.15086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。